Video B-Roll via On-Demand and Satellite - New Schizophrenia Treatment Now Available in Canada

    TORONTO, Feb. 6 /CNW/ - The following B-Roll is available at the listed
times and co-ordinates:

    On-Demand Coordinates/URL: Available at 1PM ET

    CNW Broadcast On-Demand provides free, secure and easy-to-use broadcast
quality material direct from our website to accredited journalists worldwide.
    Please contact to request login rights

    Live Satellite Coordinates:

    DATE OF FEED:  Wednesday, February, 6, 2008
    TIME OF FEED:  1:00-1:30PM ET
    CO-ORDINATES:  Anik F2 C
                   Transponder 1B
                   Audio subcarrier 6.2 and 6.8
                   Downlink frequency 3740 vertical
    TOC            CFA TX 1

    STORY SUMMARY: MONTREAL, February 6, 2008 - Canadians with schizophrenia
now have a new treatment option to manage their disease. Health Canada has
approved ZELDOX(TM) (ziprasidone hydrochloride) for the treatment of
schizophrenia and related psychotic disorders, bringing an important
additional option to manage this chronic complex mental illness, which is
highly stigmatized and misunderstood.
    New research from Léger Marketing reveals the extent of the stigma
associated with the disease. Seventy per cent of Canadians feel that those who
suffer from schizophrenia are not always treated the same way as people who
are not afflicted with the disease. Even more surprising is the fact that
among those Canadians who have been personally diagnosed or know someone who
has schizophrenia, 44 per cent say they would be uncomfortable having a person
with schizophrenia spend the weekend in their home.
    "ZELDOX(TM) is a welcome new treatment option because it controls the
symptoms of schizophrenia and appears to cause less weight gain than other
antipsychotic medications. Weight gain can increase the risk of developing
diabetes and heart disease. These side effects are often distressing and
stigmatizing and are a major reason that patients go off their medication,"
said Dr. Ashok Malla, Director of the Prevention and Early Intervention
Program for Psychoses at the Douglas Mental Health University Institute in
Montreal, Quebec. "ZELDOX(TM) has demonstrated an excellent safety and
efficacy profile as demonstrated through over a decade of research and patient
    The Léger survey revealed the low level of awareness among Canadians
about the impact of the side effects associated with many medications that are
used to treat schizophrenia. Only one in ten Canadians (10 per cent) believes
that those with schizophrenia stop their treatment due to weight gain and
other side effects. Surprisingly, 57 per cent of Canadians who have been or
know someone that has been diagnosed with schizophrenia believe that people
with the illness stop their treatment because they are well enough.
    In Canada, one in every hundred persons lives with schizophrenia - over
300,000 Canadians in all. It is characterized by symptoms such as delusions,
hallucinations, unusual suspiciousness, becoming withdrawn, and becoming
depressed or anxious. People who suffer from schizophrenia have difficulty
performing tasks that require abstract memory and sustained attention.
    Mary K. was diagnosed with schizophrenia in 2001. Frustrated by the fact
that the first treatment she took caused her to gain almost 20 pounds, she
found herself feeling exhausted and hungry all the time and she was unable to
hold down a job. When her doctor suggested that she participate in a clinical
trial evaluating the efficacy of ziprasidone, she was enthusiastic at the
prospect of trying a new treatment. Almost immediately after taking
ZELDOX(TM), Mary was able to lose the weight she had gained and felt more
energized. She was able to go back to school, earn a diploma and obtain a
steady job. She has now been taking ZELDOX(TM) for the treatment and
management of her schizophrenia for the past five years through a
compassionate use program following participation in a clinical trial.
    "Since I began taking ZELDOX(TM), I can not only manage my symptoms, but
I don't experience any of the side effects such as weight gain that were
typical of other medications I had taken. ZELDOX(TM) has enabled me not only
to regain control of my life but it has allowed me to enjoy my life."
    The precise cause of schizophrenia remains unknown and there is no
definitive cure. In 2006, the total cost of schizophrenia (both direct and
indirect) in Canada was estimated to be $4.35 billion. It also places a
substantial financial burden on sufferers themselves and their caregivers.
    "The approval of ZELDOX(TM) represents a significant step forward for
Canadians living with schizophrenia. It provides them with another option with
which to treat this chronic mental condition, a condition that has a
significant impact not only on individuals living with schizophrenia, but also
on their families and on society," said Dr. Bernard Prigent, Vice-President,
Medical Affairs, Pfizer Canada.

    About ZELDOX(TM)

    Discovered and developed by Pfizer, ZELDOX(TM) is a serotonin and
dopamine antagonist which treats the symptoms characterized as both positive
(e.g. visual and auditory hallucinations) and negative (lack of motivation and
social withdrawal) as well as the overall psychopathology of the disease.
    The efficacy of ZELDOX(TM) in the treatment of schizophrenia was
established in the largest ever clinical trials program conducted for a novel
antipsychotic medication prior to launch. The program involved four short-term
and one long-term placebo-controlled clinical trials of psychotic inpatients
who met the DSM-III-R criteria for schizophrenia. Each study included 2-3
fixed doses of ZELDOX(TM) as well as placebo. In clinical trials, ZELDOX(TM)
demonstrated excellent positive, negative, and affective symptom efficacy as
well as improvement in social impairment and cognitive symptoms in switch
studies at 6 weeks versus olanzapine and risperidone. Several instruments were
used to assess psychiatric signs and symptoms in these studies, among them the
Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome
Scale (PANSS), both multi-item inventories of psychopathology traditionally
used to evaluate the effects of drug treatment in psychosis.
    As with many other atypical antipsychotics, the exact mechanism of action
of ZELDOX(TM) is unknown. However, it has been proposed that the efficacy of
this drug in schizophrenia is mediated through a combination of dopamine type
2 (D2) and serotonin type 2 (5HT2) antagonism. ZELDOX(TM) is the only atypical
antipsychotic with data showing long-term improvement in metabolic parameters
including weight, cholesterol and triglycerides. The most common side effects
of ZELDOX(TM) include fatigue, nausea or upset stomach, constipation,
dizziness, restlessness, abnormal movements, diarrhea, rash or increased
cough/runny nose. One potential side effect of ZELDOX(TM) is that it may
induce an abnormal heart rhythm, a risk that can be increased in patients who
already have certain abnormal heart conditions or in those who are taking
certain medications. ZELDOX(TM) is not recommended in patients who have Long
QT Syndrome (LQTS), those who have had a recent heart attack, severe heart
failure or certain irregularities of heart rhythm.
    ZELDOX(TM) has been approved in 89 other countries worldwide and is
marketed under the brand name GEODON in some countries, including the United

    About Pfizer Canada Inc.

    Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, the world's
leading pharmaceutical company. Pfizer discovers, develops, manufactures and
markets prescription medicines for humans and animals. Pfizer's ongoing
research and development activities focus on a wide range of therapeutic areas
following our guiding aspiration...Working for a healthier world. For more
information, visit

    Pfizer Canada 514/693-4766 or 514/208.5960
or Farah Meghji
    Thornley Fallis Communications 416/515-7517 x249

    For technical information DURING the satellite feed, please call CNW at
(416) 863-5615.

    CNW Broadcast On-Demand provides free, secure and easy-to-use broadcast
quality material direct from our website to accredited journalists worldwide. 
   Please contact to get immediate access.

    As with all CNW Broadcast feeds, this release is offered for your free
and unrestricted news use. Comments regarding the content and quality are

For further information:

For further information: CNW BROADCAST, TORONTO, (416) 863-9350

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890